Sprouts Farmers Market closes $600 million revolving credit facility
OCEANSIDE, California - AOTI, Inc. (AIM:AOTI), a medical technology company specializing in wound healing and amputation prevention, has announced an upcoming live presentation to discuss the company’s preliminary results. The event, scheduled for April 28, 2025, at 11:30 BST, will be hosted via Investor Meet Company, a platform that facilitates interactive meetings between investors and companies.
Dr. Mike Griffiths, CEO and President, together with CFO Jayesh Pankhania, will lead the presentation. The session will be accessible to all interested parties, including current and prospective shareholders. Participants are encouraged to submit questions in advance through the Investor Meet Company dashboard until April 27, or they may pose questions during the live event.
AOTI, founded in 2006 and headquartered in Oceanside, California, with an additional base in Galway, Ireland, is recognized for its innovative approach to treating severe and chronic wounds. The company’s patented Topical Wound Oxygen (TWO2®) therapy has been shown to significantly reduce the recurrence of Diabetic Foot Ulcers (DFUs), with studies reporting an 88% decrease in hospitalizations and a 71% reduction in amputations over a 12-month period. This non-invasive therapy, which is FDA-approved among other international regulatory clearances, allows patients to self-administer treatment at home, thereby enhancing accessibility and compliance.
Investors interested in attending the presentation can sign up for free with Investor Meet Company and request to meet AOTI, Inc. Those who already follow AOTI on the platform will be automatically invited to the event.
This upcoming investor presentation provides an opportunity for AOTI to share its financial performance and for investors to engage directly with the company’s leadership. The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.